Sprout Pharmaceuticals

31 articles about Sprout Pharmaceuticals

• Sprout Pharmaceuticals Announces Release of Abstract Reporting Positive Interim Results for Flibanserin in Breast Cancer Patients Suffering from Low Libido for Poster Discussion at 2023 ASCO Annual Meeting

  6/2/2023

  Sprout Pharmaceuticals, Inc. a pharmaceutical company specializing in women's sexual health announced publication of abstract 12015 by the American Society of Clinical Oncology.

• Memorial Sloan Kettering Cancer Center (MSK) Shares Positive Preliminary Results of Flibanserin in Breast Cancer Patients Suffering from Low Libido

  3/15/2022

  New research from Memorial Sloan Kettering Cancer Center led by medical oncologist Shari Goldfarb, MD, and colleagues, reports positive findings for the use of Addyi tablets in breast cancer patients on endocrine therapy who are suffering from treatment- or disease- induced low libido.

• 

  Clinical Catch-Up: March 2-6

  3/9/2020

  It was a relatively quiet week for clinical trial announcements. Here’s a look.

• Addyi Demonstrates Significant Improvements in Female Sexual Function for Arousal, Desire, Lubrication, Satisfaction, and Orgasm

  3/5/2020

  Presented at The International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting, results from three pivotal, randomized, placebo-controlled trials assessing efficacy of Addyi in treating premenopausal women with Hypoactive Sexual Desire Disorder, or HSDD, show clear benefits in multiple areas of female sexual function in as early as 4 weeks and maintained for duration of treatment.

• The Food and Drug Administration (FDA) Determines that Women Taking Addyi May Safely Consume Alcohol

  4/12/2019

  Sprout Pharmaceuticals is pleased to announce that the FDA has decided that existing warnings and restrictions regarding alcohol use in women taking Addyi® (flibanserin) for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) are overly restrictive and overstate the risk of alcohol interaction.

• 

  FDA Orders Safety Label Change for Addyi Regarding Alcohol Consumption

  4/12/2019

  Sprout wanted the warning regarding alcohol to be completely removed but the FDA said it must remain, although with a caveat.

• FDA orders important safety labeling changes for Addyi

  4/11/2019

  The U.S. Food and Drug Administration today issued a safety labeling change order to Sprout Pharmaceuticals for their drug, Addyi (flibanserin), that requires the company to revise important safety information that women and their health care professionals need to have when considering use of the drug.

• Sprout Pharmaceuticals Presents Important New Addyi Safety and Tolerability Data through Three Alcohol Interaction Studies in Which There Was No Syncope or Orthostatic Hypotension Requiring Medical Attention

  3/21/2019

  Multiple studies and new data clarifying the Addyi and alcohol interaction for both the medical community and patients were formally submitted to the FDA as well as presented to The International Society for the Study of Women's Sexual Health (ISSWSH), International Society for Sexual Medicine (ISSM) and Sexual Medicine Society of North America (SMSNA).

• 

  Sprout Relaunches Female Sex Drive Pill Addyi at Half the Price Charged Under Valeant

  6/28/2018

  After failing to gain market share under the umbrella of Valeant Pharmaceuticals, Addyi is getting a relaunch at half the price.

• Valeant Completes Sale of Sprout Pharma Subsidiary to Former Shareholders of Sprout Pharma

  12/21/2017

  Valeant today announced that its affiliate has completed the divestiture of the Sprout to Sprout2, an entity affiliated with certain former shareholders of Sprout, in exchange for a 6% royalty on global sales of ADDYI beginning in May 2019.

• 

  Valeant Sells Sprout Pharma to a New Company 'Associated' With Sprout Founders

  11/6/2017

  A little more than two years after acquiring Sprout, Valeant is selling off the developer of the female sex drive drug Addyi.

• Investors Behind Sprout Accuse Valeant of Bungling Marketing of Female Libido Drug

  11/3/2016

• Sprout Team Withers as Valeant Terminates 140 Sales Contractors for the Female Libido Drug

  4/6/2016

• Sprout CEO Cindy Whitehead Steps Down After Bringing the Little Pink Pill to Market

  12/11/2015

• Sprout Release: Addyi (Flibanserin), First-Ever Medical Treatment For Acquired, Generalized HSDD In Premenopausal Women, Now Available

  10/19/2015

• Sprout’s Female Libido Drug Brings Up More FDA Dissent and Men-Oriented Testing

  9/17/2015

• Valeant Acquires Female Sex Drive Drug Maker Sprout for $1 Billion

  8/21/2015

• Sprout's First-Ever Female Libido Drug Comes With Boxed Warning and Controversy

  8/20/2015

• Sprout's Libido Pill Won't Come Close To Viagra's Impact

  8/19/2015

• Sprout to Expand to 200 Employees After FDA Approval of Female Sex-Drive Drug

  8/19/2015